Cancer incidence during the COVID-19 pandemic by region of residence in Manitoba, Canada: A cancer registry-based interrupted time series study.
COVID-19 pandemic
cancer
incidence
region
Journal
Cancer medicine
ISSN: 2045-7634
Titre abrégé: Cancer Med
Pays: United States
ID NLM: 101595310
Informations de publication
Date de publication:
16 Nov 2023
16 Nov 2023
Historique:
revised:
13
09
2023
received:
08
08
2023
accepted:
26
10
2023
medline:
17
11
2023
pubmed:
17
11
2023
entrez:
17
11
2023
Statut:
aheadofprint
Résumé
Health care in Manitoba, Canada is divided into five regions, each with unique geographies, demographics, health care access, and health status. COVID-19-related restrictions and subsequent responses also differed by region. To understand the impact of the pandemic on cancer incidence in the context of these differences, we examined age-standardized cancer incidence rates by region over time before and after the COVID-19 pandemic. We used a population-based quasi-experimental study design, population-based data, and an interrupted time series analysis to examine the rate of new cancer diagnoses before (January 2015 until December 2019) and after the start of COVID-19 and the interventions implemented to mitigate its impact (April 2020 until December 2021) by region. Overall cancer incidence differed by region and remained lower than expected in Winnipeg (4.6% deficit, 447 cases), Prairie Mountain (6.9% deficit, 125 cases), and Southern (13.0% deficit, 238 cases). Southern was the only region that had a significantly higher deficit in cases compared to Manitoba (ratio 0.92, 95% CI 0.86, 0.99). Breast and colorectal cancer incidence decreased at the start of the pandemic in all regions except Northern. Lung cancer incidence decreased in the Interlake-Eastern region and increased in the Northern region. Prostate cancer incidence increased in Interlake-Eastern. The impact of the COVID-19 pandemic on cancer incidence differed by region. The deficit in the number of cases was largest in the southern region and was highest for breast and prostate cancers. Cancer incidence did not significantly decrease in the most northern, remote region.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : CIHR
ID : 179890
Pays : Canada
Informations de copyright
© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Références
Aboulatta L, Kowalec K, Delaney J, et al. Trends of COVID-19 incidence in Manitoba and public health measures: March 2020 to February 2022. BMC Res Notes. 2022;15(1):162. doi:10.1186/s13104-022-06049-5
Power T, Wilson D, Best O, et al. COVID-19 and indigenous peoples: an imperative for action. J Clin Nurs. 2020;29(15-16):2737-2741. doi:10.1111/jocn.15320
Manitoba Health. Changes to public health orders and new system protocols. 2021. Accessed July 18, 2023. https://news.gov.mb.ca/asset_library/en/newslinks/2021/10/BACKGROUNDER-CHANGES_TO_PUBLIC_HEALTH_ORDERS.pdf
Unruh L, Allin S, Marchildon G, et al. A comparison of 2020 health policy responses to the COVID-19 pandemic in Canada, Ireland, the United Kingdom and the United States of America. Health Policy. 2022;126(5):427-437. doi:10.1016/j.healthpol.2021.06.012
Rittberg R, Mann A, Desautels D, Earle CC, Navaratnam S, Pitz M. Canadian Cancer Centre response to COVID-19 pandemic: a national and provincial response. Curr Oncol. 2020;28(1):233-251. doi:10.3390/curroncol28010026
Decker KM, Feely A, Bucher O, et al. New cancer diagnoses before and during the COVID-19 pandemic. JAMA Network Open. 2023;6(9):e2332363. doi:10.1001/jamanetworkopen.2023.32363
Organisation for Economic Co-operation and Development (OECD). The territorial impact of COVID-19: managing the crisis across levels of government. 2020. Accessed April 20, 2023. https://www.oecd.org/coronavirus/policy-responses/the-territorial-impact-of-covid-19-managing-the-crisis-across-levels-of-government-d3e314e1/#section-d1e2449
Manitoba Health. Population Report-June 1, 2020. Government of Manitoba; 2023. Accessed February 6, 2023. https://www.gov.mb.ca/health/population/
Roussin B. Health status of Manitobans 2022: healthy communities: a role for everyone. 2023: 1-78. Accessed July 20, 2023. https://www.gov.mb.ca/health/cppho/docs/health-status-2022.pdf
Righolt CH, Zhang G, Sever E, Wilkinson K, Mahmud SM. Patterns and descriptors of COVID-19 testing and lab-confirmed COVID-19 incidence in Manitoba, Canada, March 2020-May 2021: a population-based study. Lancet Reg Health Am. 2021;2:100038. doi:10.1016/j.lana.2021.100038
Kives B. 2 Years into the Pandemic, Manitoba Suffers Canada's 2nd-Highest COVID-19 Death Rate. CBC; 2022. Accessed June 27, 2023. https://www.cbc.ca/news/canada/manitoba/manitoba-covid-death-rate-two-years-in-1.6378601
North American Association of Central Cancer Registries. Appendix C-data quality indicators by year and registry. In: Hotes Ellison J, Wu XC, McLaughlin C, Lake A, Firth R, Cormier M, eds. Cancer in North America: 1999-2003 Volume One: Incidence. North American Association of Central Cancer Registries; 2006:475-486.
Lopez Bernal J, Cummins S, Gasparrini A. Interrupted time series regression for the evaluation of public health interventions: a tutorial. Int J Epidemiol. 2017;46(1):348-355.
Rodriguez G. Generalized Linar Models. 4. A Model for Overdispersed Count Data. Princeton University; 2021. Accessed May 21, 2021. https://data.princeton.edu/wws509/r/overdispersion
Hartig F. DHARMa: Residual Diagnostics for Hierarchical (Multi-Level/Mixed) Regression Models. University of Regensberg; 2021. Accessed May 21, 2021. https://cran.r-project.org/web/packages/DHARMa/vignettes/DHARMa.html
McFadden D. Conditional logit analysis of qualitative choice behavior. In: Zarembka P, ed. Frontiers in Econometrics. Academic Press; 1974:104-142.
Wickham H, Miller E, Smith D. Data from: Haven: Import and Export ‘SPSS’, ‘Stata’ and ‘SAS’ Files. r-project.org; 2022.
Harrell Jr FE. Data from: Hmisc: Harrell Miscellaneous. r-project.org; 2021.
Sarkar D. Lattice: Multivariate Data Visualization with R. Springer; 2008.
Venables WN, Ripley BD. Modern Applied Statistics with S. 4th ed. Springer; 2002.
Wickham H. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag; 2016.
Hartig F. Data from: DHARMa: Residual Diagnostics for Hierarchical (Multi-Level/ Mixed) Regression Models. R Package Version 0.4.5. r-project.org; 2022.
Hothorn T, Bretz F, Westfall P. Simultaneous inference in general parametric models. Biom J. 2008;50(3):346-363.
Zeileis A, Hothorn T. Diagnostic checking in regression relationships. R News. 2002;2(3):7-10.
Gordon M, Lumley T. Data from: Forest Plot: Advanced Forest Plot Using ‘grid’ Graphics. R Package Version 2.0.1. r-project.org; 2021.
Decker KM, Lambert P, Feely A, et al. Evaluating the impact of the COVID-19 pandemic on new cancer diagnoses and oncology Care in Manitoba. Curr Oncol. 2021;28(4):3081-3090. doi:10.3390/curroncol28040269
Rathod S, Dubey A, Chowdury A, Bashir B, Koul R. A call for a radiation oncology model based on new 4Rs during the COVID-19 pandemic. Adv Rad Oncol. 2020;5(4):608-609. doi:10.1016/j.adro.2020.04.013
Decker KM, Feely A, Bucher O, Singh H, Turner D, Lambert P. Evaluating the impact of the COVID-19 pandemic on cancer screening in a Central Canadian province. Prev Med. 2022;155:106961. doi:10.1016/j.ypmed.2022.106961
Friberg S, Mattson S. On the growth rates of human malignant tumors: implications for medical decision making. J Surg Oncol. 1997;65(4):284-297. doi:10.1002/(sici)1096-9098(199708)65:4%3C284::aid-jso11%3E3.0.co;2-2
Alaidy Z, Mohamed A, Euhus D. Breast cancer progression when definitive surgery is delayed. Breast J. 2021;27(4):307-313. doi:10.1111/tbj.14177
Strandberg R, Czene K, Eriksson M, Hall P, Humphreys K. Estimating distributions of breast cancer onset and growth in a Swedish mammography screening cohort. Cancer Epidemiol Biomarkers Prev. 2022;31(3):569-577. doi:10.1158/1055-9965.EPI-21-1011
Beltramo G, Cottenet J, Mariet AS, et al. Chronic respiratory diseases are predictors of severe outcome in COVID-19 hospitalised patients: a nationwide study. Eur Respir J. 2021;58(6):2004474. doi:10.1183/13993003.04474-2020
Passaro A, Bestvina C, Velez Velez M, Garassino MC, Garon E, Peters S. Severity of COVID-19 in patients with lung cancer: evidence and challenges. J Immunother Cancer. 2021;9(3):1-10. doi:10.1136/jitc-2020-002266
Mogharab V, Ostovar M, Ruszkowski J, et al. Global burden of the COVID-19 associated patient-related delay in emergency healthcare: a panel of systematic review and meta-analyses. Global Health. 2022;18(1):58. doi:10.1186/s12992-022-00836-2
Jones D, Neal RD, Duffy SRG, Scott SE, Whitaker KL, Brain K. Impact of the COVID-19 pandemic on the symptomatic diagnosis of cancer: the view from primary care. Lancet Oncol. 2020;21(6):748-750. doi:10.1016/S1470-2045(20)30242-4
Greene G, Griffiths R, Han J, et al. Impact of the SARS-CoV-2 pandemic on female breast, colorectal and non-small cell lung cancer incidence, stage and healthcare pathway to diagnosis during 2020 in Wales, UK, using a national cancer clinical record system. Br J Cancer. 2022;127(3):558-568. doi:10.1038/s41416-022-01830-6
Canadian Cancer S. Canadian Cancer Statistics. A 2018 Special Report on Cancer Incidence by Stage. Canadian Cancer Society; 2018. Accessed August 2, 2023, https://cancer.ca/en/research/cancer-statistics/canadian-cancer-statistics
Bell N, Connor Gorber S, Shane A, et al. Recommendations on screening for prostate cancer with the prostate-specific antigen test. CMAJ. 2014;186(16):1225-1234. doi:10.1503/cmaj.140703